Alps Advisors Inc. lowered its holdings in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 278,504 shares of the biopharmaceutical company’s stock after selling 11,856 shares during the period. Alps Advisors Inc. owned about 0.20% of Achillion Pharmaceuticals worth $1,003,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Achillion Pharmaceuticals by 142.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,227 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 4,247 shares during the last quarter. Bank of Montreal Can bought a new stake in Achillion Pharmaceuticals in the 2nd quarter worth $30,000. Meeder Asset Management Inc. grew its holdings in Achillion Pharmaceuticals by 677.1% in the 3rd quarter. Meeder Asset Management Inc. now owns 19,551 shares of the biopharmaceutical company’s stock worth $70,000 after acquiring an additional 17,035 shares during the last quarter. Paloma Partners Management Co bought a new stake in Achillion Pharmaceuticals in the 2nd quarter worth $74,000. Finally, Jane Street Group LLC bought a new stake in Achillion Pharmaceuticals in the 2nd quarter worth $78,000. 78.77% of the stock is currently owned by institutional investors.

Shares of NASDAQ ACHN opened at $6.36 on Monday. Achillion Pharmaceuticals, Inc. has a 1 year low of $1.29 and a 1 year high of $6.46. The stock has a market cap of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67. The firm has a 50-day moving average of $4.93 and a 200 day moving average of $3.79.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. On average, research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price target on the stock. in a report on Tuesday, August 27th. BidaskClub lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 12th. Svb Leerink lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $5.00 to $6.30 in a report on Friday, October 18th. JMP Securities lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Leerink Swann cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 target price for the company. in a research report on Friday, October 18th. Three analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $4.96.

In other Achillion Pharmaceuticals news, CEO Joseph Truitt sold 133,484 shares of Achillion Pharmaceuticals stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the transaction, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at $660,785.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.58% of the stock is currently owned by insiders.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Read More: What is channel trading?

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.